Test Your Knowledge

Quiz: What Benefit Does Fractionated CAR-T Therapy Dosing in Relapsed/Refractory ALL Provide?

10/29/2020

Recent News

News

FDA Approves Adjuvant Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer

04/19/2024

Stephanie Holland

Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.

Based on results from the phase...

04/19/2024

Oncology

News

IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization

04/19/2024

Amber Denham

According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...

According to phase 2 results,...

04/19/2024

Oncology

News

Elranatamab vs Teclistamab Treatment Among Patients With Triple-Class Exposed/Refractory Multiple Myeloma

04/19/2024

Jordan Kadish

According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...

According to findings from an...

04/19/2024

Oncology

News

Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL

04/18/2024

Amber Denham

According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.

According to phase 3b results...

04/18/2024

Oncology

News

Venetoclax With Low-Dose Cytarabine Demonstrates Efficacy, Tolerability for Patients With AML at First MRD or Oligoblastic Relapse

04/18/2024

Amber Denham

Venetoclax with low-dose cytarabine is well-tolerated and highly effective among patients with acute myeloid leukemia at first measurable residual disease or oligoblastic relapse, according to a phase 2 study.

Venetoclax with low-dose...

04/18/2024

Oncology

News

Adjuvant Alectinib Significantly Improved Disease-Free Survival Among Patients With Resected ALK-Positive Non-Small Cell Lung Cancer

04/18/2024

Stephanie Holland

According to results from the phase 3 ALINA trial, adjuvant alectinib significantly improved disease-free survival among patients with resected ALK-positive stage IB, II, or IIIA non-small cell lung cancer.

According to results from the...

04/18/2024

Oncology

News

Second- or Third-Line Giredestrant Among Patients With ER-Positive, HER2-Negative Advanced Breast Cancer

04/18/2024

Stephanie Holland

According to results from the phase 2 acelERA breast cancer study, giredestrant showed a favorable trend toward benefit in investigator-assessed progression-free survival among previously treated patients with ESR1-mutated, ER-positive,...

According to results from the...

04/18/2024

Oncology

News

Pazopanib Failed to Improve Long-Term Survival Results Among Patients With Metastatic Renal Cell Carcinoma Post-Metastasectomy at High Risk of Recurrence

04/16/2024

Stephanie Holland

According to results from the ECOG-ACRIN E2810 study, pazopanib did not improve long-term disease-free survival or overall survival among patients with metastatic renal cell carcinoma with no evidence of disease after metastasectomy at high...

According to results from the...

04/16/2024

Oncology

News

Atezolizumab Plus Cabozantinib Failed to Improve Survival Among Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer

04/09/2024

Stephanie Holland

Results from the phase 3 CONTACT-01 trial demonstrated that atezolizumab plus cabozantinib did not improve OS or PFS compared to docetaxel among patients with metastatic NSCLC who experienced disease progression after prior treatment.

Results from the phase 3...

04/09/2024

Oncology

News

Potential Benefits From Neoadjuvant Chemotherapy for Patients With Locally Advanced Colon Cancer

04/09/2024

Stephanie Holland

Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.

Results from the phase 3 OPTICAL...

04/09/2024

Oncology